Novel vaccine approach proves powerful against Zika virus

August 6, 2018, The Ohio State University
Transmission electron microscope image of negative-stained, Fortaleza-strain Zika virus (red), isolated from a microcephaly case in Brazil. The virus is associated with cellular membranes in the center. Credit: NIAID

A uniquely designed experimental vaccine against Zika virus has proven powerful in mice, new research has found.

A team led by researchers at The Ohio State University has developed and tested a that employs an uncommon two-pronged approach to fighting the , which is spread by mosquitos and is most serious for pregnant women and their fetuses.

The single-dose vaccine, carrying the genes for two or three Zika proteins, proved effective in triggering an that prevented later infection by Zika virus, according to the study, which appears in the journal Nature Communications.

"In this study, the vaccine was potent, safe and highly effective, at least in the short term. There's a long way to go, but we think this is a promising candidate for a human vaccine," said Jianrong Li, an Ohio State professor of veterinary biosciences who led the study and developed the vaccine platform.

Babies born to Zika-infected mothers are sometimes born with a birth defect called microcephaly. Other complications include miscarriage, stillbirth and other birth defects. Research also suggests that a small percentage of people infected with the virus can contract Guillain-Barre syndrome, which affects the nervous system.

There's no vaccine available currently—though some are in clinical trials—and the only protection against Zika are preventative measures such as insect repellant, staying indoors and wearing long sleeves and pants.

Shan-Lu Liu, a study co-author and director of Ohio State's Viruses and Emerging Pathogens Program, said the holds particular promise because it appears to afford an adequate immune response with one dose. In hard-to-reach and resource-poor areas, that becomes especially valuable, he said.

When this study began, the Ohio State team wondered if a novel approach to vaccination might prove effective against the virus—one in which they targeted a protective immune response by expressing two or three Zika proteins.

As a vehicle for the Zika proteins, they looked to vesicular stomatitis virus, or VSV, which is a foot-and-mouth disease in cattle. The weakened form of the virus is harmless in humans and mice. VSV has been used in other vaccines, including a successful Ebola vaccine which has been used in preventing outbreaks in humans in Africa.

"It's a good platform for human vaccines, because people don't have any antibodies against it and that allows VSV to successfully transport the vaccine without being stopped by the immune system," said study co-author Mark Peeples, a pediatrics professor at Ohio State and researcher at Nationwide Children's Hospital in Columbus.

In general, vaccines work by delivering harmless amounts of the target virus proteins to the bloodstream, allowing the body to build up immune responses that will provide protection in the event of subsequent exposure to the virus. Li's work has been focused on weakening VSV so that it doesn't cause any problems and then inserting genes from other viruses to make powerful vaccines, said Peeples, who first encouraged Li to consider applying his vaccine platform to Zika.

In the experimental vaccine, VSV acts as a vehicle to deliver the genes for two or three key proteins from the Zika virus, carrying them into the mouse and expressing them inside some of the cells in the mouse so that the immune system could respond and build up a defense against Zika.

"The addition of NS1 protein is an innovative approach for a vaccine—it's a protein that is made after the Zika virus infects a cell. It's what this bug uses to replicate itself once it's inside the host," said Prosper Boyaka, a study co-author and Ohio State professor of veterinary biosciences.

The study included experiments in mice with severely compromised immune systems—a necessary step to make sure that mice could get sick after infection with Zika virus. When the vaccinated mice were exposed to Zika virus, their weak immune systems fought it off swiftly and efficiently, convincing the research team that their design had worked.

Without using the immunocompromised animals, the researchers would not have known how safe and effective the vaccine was, Peeples said.

The early success with this vaccine has encouraged this team to use the same approach to fight other related viruses, including Dengue fever, the researchers said.

The researchers also looked at the response to a vaccine with just the unique NS1 gene inserted into VSV and for the first time established that it offered partial protection all on its own, confirming its value in the vaccine, Boyaka said.

"We are very excited to find that VSV-based Zika vaccine is highly promising in both immunocompetent and immunocompromised mice", said Anzhong Li, who is the first author of the paper and a graduate student in Jianrong Li's laboratory. Anzhong Li recently presented these findings at a scientific conference in Italy.

"Really, the next big question is 'Will this be protective in humans?' " Peeples said.

Explore further: Development of a novel vaccine for Zika

Related Stories

Development of a novel vaccine for Zika

June 5, 2017
Research presented by Farshad Guirakhoo, Ph.D., Chief Scientific Officer, GeoVax, Inc., at the ASM Microbe 2017 meeting showed a new Zika virus vaccine that gives 100% protection in mice. The vaccine is the first to be based ...

Trials show inactivated Zika virus vaccine is safe and immunogenic

December 5, 2017
The investigational Zika purified inactivated virus (ZPIV) vaccine was well-tolerated and induced an immune response in participants, according to initial results from three Phase 1 clinical trials. Scientists at the Walter ...

The first live-attenuated vaccine candidate completely protects mice against Zika infection

April 10, 2017
The first live-attenuated Zika vaccine still in the development stage completely protected mice against the virus after a single vaccination dose, according to new research from The University of Texas Medical Branch at Galveston ...

Zika vaccine protects fetus against infection and birth defects

July 13, 2017
Immunizing female mice with a Zika vaccine can protect their developing fetus from infection and birth defects during pregnancy, according to new research from The University of Texas Medical Branch at Galveston. The findings ...

DNA-based Zika vaccine is safe and effective at inducing immune response

October 4, 2017
A new generation DNA-based Zika vaccine demonstrated both safety and ability to elicit an immune response against Zika in humans in a phase 1 clinical trial conducted through a partnership among the Perelman School of Medicine ...

More evidence that Zika mRNA vaccines can stop viral replication in mice

February 17, 2017
Vaccine developers have successfully protected mice against Zika by injecting synthetic messenger RNA that encodes for virus proteins into the animals. The cells of the mice then build parts of the virus, training the immune ...

Recommended for you

Tibetan sheep highly susceptible to human plague, originates from marmots

August 16, 2018
In the Qinghai-Tibet plateau, one of the region's highest risk areas for human plague, Himalayan marmots are the primary carriers of the infectious bacterium Y. pestis. Y. pestis infection can be transmitted to humans and ...

Autoimmunity plays role in development of COPD, study finds

August 16, 2018
Autoimmunity plays a role in the development of chronic obstructive pulmonary disease (COPD), according to a study led by Georgia State University and Vanderbilt University Medical Center that analyzed human genome information ...

Scientists identify nearly 200 potential tuberculosis drug targets

August 16, 2018
Tuberculosis is one of the top 10 causes of death worldwide. Nearly 2 million people die every year from this infectious disease, and an estimated 2 billion people are chronically infected. The only vaccine, developed almost ...

Reliable point-of-care blood test can help prevent toxoplasmosis

August 16, 2018
A recent study, performed in Chicago and Rabat, Morocco, found that a novel finger-prick test for infection with the parasite Toxoplasma gondii during pregnancy—and many other potential applications—is 100 percent sensitive ...

First mouse model to mimic lung disease could speed discovery of more effective treatments

August 16, 2018
The biggest hurdle to finding effective therapies for idiopathic pulmonary fibrosis (IPF) – a life-threatening condition in which the lungs become scarred and breathing is increasingly difficult – has been the inability ...

Anticancer drug offers potential alternative to transplant for patients with liver failure

August 15, 2018
Patients suffering sudden liver failure could in the future benefit from a new treatment that could reduce the need for transplants, research published today shows.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.